Genetic basis for developmental toxicity due to statin intake using embryonic stem cell differentiation model

Area of Science:

• Developmental Biology
• Pharmacology
• Genetics

Background:

• The in utero environment critically influences embryonic development.
• The effects of statin medications on fetal development are not well understood, with conflicting data from animal and human studies.
• Lipophilic statins are commonly prescribed, raising concerns about potential developmental toxicity.

Purpose of the Study:

• To investigate the effects of lipophilic statins (simvastatin, atorvastatin) on early embryonic development using an in vitro model.
• To assess the impact of statins on the differentiation of embryonic stem cells into ectodermal, mesodermal, and endodermal lineages.
• To identify specific developmental pathways affected by statin exposure.

Main Methods:

• Utilized an in vitro embryonic stem cell differentiation model mimicking early embryonic development.
• Systematically exposed differentiating cells to simvastatin and atorvastatin at various concentrations and critical developmental time points.
• Quantified the expression levels of key lineage-specific genes using quantitative polymerase chain reaction (qPCR).

Main Results:

• Mesodermal lineage genes (brachyury, Flk-1, Nkx2.5, α/β-myosin heavy chain) exhibited the highest sensitivity to statin exposure.
• Statins altered the expression of endodermal (α-fetoprotein) and ectodermal (Nes, Neurofilament 200 kDa) markers.
• Observed changes suggest statin-induced alterations in critical signaling pathways during early differentiation.

Conclusions:

• Exposure to lipophilic statins during early embryonic differentiation significantly impacts gene expression across multiple germ layers.
• The mesodermal lineage appears particularly vulnerable to statin-induced developmental disruption.
• These findings provide a potential mechanistic link between maternal statin use and congenital abnormalities in the heart and limbs.